Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism
Main Author: | |
---|---|
Publication Date: | 2014 |
Other Authors: | , |
Format: | Article |
Language: | eng |
Source: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Download full: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000300008 |
Summary: | Background: Rhabdomyolysis is a condition defined by necrosis of muscle cell and release of its contents into the systemic circulation. The fibric acid derivative fenofibrate is indicated in the treatment of hyperlipidaemia in adults. Fenofibrate monotherapy-induced rhabdomyolysis is rare. The presence of chronic renal failure and hypothyroidism are among the primary factors for rhabdomyolysis. Case: Our case study is about an adolescent with chronic renal failure, severe hypertriglyceridemia and hypothyroidism who developed rhabdomyolysis and irreversible deterioration of kidney function after monotherapy with fenofibrate. The patient required renal replacement therapy using haemodialysis and kidney transplant. Conclusion: This case study is of the highest importance to warn against the adverse events associated with fenofibrate therapy and to alert to the need of a rigorous control of its use when risk factors are present. |
id |
RCAP_925a6dddc02054f74446ac40921ca0a4 |
---|---|
oai_identifier_str |
oai:scielo:S0872-01692014000300008 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidismChronic renal failurefenofibratehypothyroidismrhabdomyolysisBackground: Rhabdomyolysis is a condition defined by necrosis of muscle cell and release of its contents into the systemic circulation. The fibric acid derivative fenofibrate is indicated in the treatment of hyperlipidaemia in adults. Fenofibrate monotherapy-induced rhabdomyolysis is rare. The presence of chronic renal failure and hypothyroidism are among the primary factors for rhabdomyolysis. Case: Our case study is about an adolescent with chronic renal failure, severe hypertriglyceridemia and hypothyroidism who developed rhabdomyolysis and irreversible deterioration of kidney function after monotherapy with fenofibrate. The patient required renal replacement therapy using haemodialysis and kidney transplant. Conclusion: This case study is of the highest importance to warn against the adverse events associated with fenofibrate therapy and to alert to the need of a rigorous control of its use when risk factors are present.Sociedade Portuguesa de Nefrologia2014-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000300008Portuguese Journal of Nephrology & Hypertension v.28 n.3 2014reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000300008Marques,Filipa CarlotaViveiro,CarolinaCastro,Isabelinfo:eu-repo/semantics/openAccess2024-02-06T17:04:46Zoai:scielo:S0872-01692014000300008Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:18:53.034557Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
title |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
spellingShingle |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism Marques,Filipa Carlota Chronic renal failure fenofibrate hypothyroidism rhabdomyolysis |
title_short |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
title_full |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
title_fullStr |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
title_full_unstemmed |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
title_sort |
Fenofibrate-induced rhabdomyolysis in an adolescent with chronic renal failure and hypothyroidism |
author |
Marques,Filipa Carlota |
author_facet |
Marques,Filipa Carlota Viveiro,Carolina Castro,Isabel |
author_role |
author |
author2 |
Viveiro,Carolina Castro,Isabel |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Marques,Filipa Carlota Viveiro,Carolina Castro,Isabel |
dc.subject.por.fl_str_mv |
Chronic renal failure fenofibrate hypothyroidism rhabdomyolysis |
topic |
Chronic renal failure fenofibrate hypothyroidism rhabdomyolysis |
description |
Background: Rhabdomyolysis is a condition defined by necrosis of muscle cell and release of its contents into the systemic circulation. The fibric acid derivative fenofibrate is indicated in the treatment of hyperlipidaemia in adults. Fenofibrate monotherapy-induced rhabdomyolysis is rare. The presence of chronic renal failure and hypothyroidism are among the primary factors for rhabdomyolysis. Case: Our case study is about an adolescent with chronic renal failure, severe hypertriglyceridemia and hypothyroidism who developed rhabdomyolysis and irreversible deterioration of kidney function after monotherapy with fenofibrate. The patient required renal replacement therapy using haemodialysis and kidney transplant. Conclusion: This case study is of the highest importance to warn against the adverse events associated with fenofibrate therapy and to alert to the need of a rigorous control of its use when risk factors are present. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-09-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000300008 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000300008 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692014000300008 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Nefrologia |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Nefrologia |
dc.source.none.fl_str_mv |
Portuguese Journal of Nephrology & Hypertension v.28 n.3 2014 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137279045795840 |